Drug Trial Radar · NCT01018134
Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study
Last checked: Nov 20, 2026Latest source record: Aug 5, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
151
Actual
Start
Nov 2009
Primary completion
May 2010
Study completion May 2010
Sponsor
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 23, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objectives of this study are to evaluate the efficacy and safety of two dosing regimens of desoximetasone 0.05% and 0.25% topical sprays as compared to a vehicle spray in patients with moderate to severe plaque psoriasis.
Conditions
- Psoriasis
Interventions
Desoximetasone 0.05% once dailyDrug
Desoximetasone topical spray 0.05% administered to affected area once daily for 28 days
Desoximetasone 0.05% twice dailyDrug
Desoximetasone topical spray 0.05% administered to affected area twice daily for 28 days
Desoximetasone 0.25% once dailyDrug
Desoximetasone topical spray 0.25% administered to affected area once daily for 28 days
Desoximetasone 0.25% once dailyDrug
Desoximetasone topical spray 0.25% administered to affected areas twice daily for 28 days
Vehicle once dailyDrug
Vehicle topical spray administered to affected areas once daily for 28 days
Vehicle twice dailyDrug
Vehicle topical spray administered to affected areas twice daily for 28 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants in Each Treatment Group With Clinical Cure: Physician's Global Assessment (PGA) Score = 0 or 1 at Day 28Time frame: 28 days
- Number of Participants in Each Treatment Group With Treatment Success for the Target Lesion (Total Lesion Severity Scale (TLSS) a Score of 0 or 1).Time frame: Day 28
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Investigator Site
Miami, Florida
Investigator Site
Martinez, Georgia
Investigator Site
Olathe, Kansas
Investigator Site
Wichita, Kansas
Investigator Site
Albuquerque, New Mexico
Investigator Site
Cincinnati, Ohio
Investigator Site
Simpsonville, South Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.